-
2024-511652-40-00
5
2025-02-05
METASTATIC CASTRATION RESISTANT PROSTATE CANCER
-
2024-519514-31-00
4
2025-01-31
metastatic triple-negative PD-L1 positive breast cancer
-
2024-519310-31-00
4
2025-01-27
Anemia due to MDS with del5q with IPSS-R very low, low, or intermediat
-
2024-511945-20-00
4
2025-01-24
patients affected by small cell lung cancer (SCLC)
-
2024-516450-21-00
6
2024-12-31
metastatic or locally advanced urothelial cancer
-
2024-514304-14-00
1
2024-10-08
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
-
2023-503317-29-00
5
2024-04-12
Metastatic renal cell carcinoma (mRCC)
-
2022-502775-29-01
5
2023-12-14
Early stage Follicular Lymphoma
-
2024-513562-19-00
5
2023-08-30
End-Stage Kidney Disease
-
2023-510431-11-00
4
2023-07-21
Chronic Lymphocytic Leukemia
-
2024-512878-98-00
9
2023-05-16
Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative
Breas
-
2024-511631-10-00
9
2023-02-27
Hodgkin’s lymphoma
-
2022-500765-27-00
5
2022-11-03
Hematologic malignancies
-
2024-511635-94-00
4
2022-07-11
Relapsed or Refractory Plasmablastic lymphoma
-
2023-504599-10-00
4
2022-03-29
Chronic lymphocytic leukemia recurrent
-
2024-510690-16-00
5
2022-01-31
Relapsed/refractory follicular lymphoma
-
2024-516330-35-00
5
2021-09-29
Non-Small Cell Lung Cancer
-
2024-514824-18-00
4
2021-09-16
chronic lymphocytic leukemia/small lymphocytic lymphoma
-
2024-518623-30-00
6
2020-10-01
metastatic castration resistant prostate cancer without mutations of B
-
2023-508302-24-00
4
2019-05-07
Locally Advanced/Metastatic Urothelial Cancer
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2024-513307-13-00
4
2025-05-26
Advanced/metastatic solid tumors including gynecological
cancers (endo
-
2024-513621-23-00
5
2025-04-18
Advanced/metastatic non-small cell lung cancer (NSCLC)
-
2024-512180-31-00
4
2025-03-14
Oligometastatic renal cell carcinoma